CBPO

China Biologic Products Holdings, Inc.

A maker of plasma-derived medicines, this Chinese biopharmaceutical company turns donated human blood plasma into therapies like human albumin, immunoglobulin, and coagulation factors used to treat immune deficiencies, infections, and trauma. Founded in 2002 and once listed on the Nasdaq as China Biologic Products, it grew out of the Shandong Province Institute of Biological Products, which dates to 1971, and now runs privately as Taibang Biologic Group. A memorable detail: for years its key subsidiary was the only plasma-based drugmaker approved by the government of Shandong, one of China's most populous provinces.

No proxy statement recorded.